Nicotinamide adenine dinuleotide (
NAD(+)) plays critical roles in multiple
biological functions. Previous studies have indicated that
NAD(+) treatment decreases oxidative stress-induced death of primary neurons and astrocytes.
Intranasal administration of
NAD(+) also reduces brain damage in a rat model of transient focal
brain ischemia. However, the mechanisms underlying this protective effect remain unknown. In this study, we used a mouse model of
brain ischemia to test our hypothesis that
NAD(+) decreases ischemic brain damage partially by preventing autophagy. Adult male mice were subjected to transient
middle cerebral artery occlusion (tMCAO) for 90min, and
NAD(+) was administered intraperitoneally (i.p.) immediately after reperfusion started. We found that administration with 50mg/kg
NAD(+) led to significant decreases in
infarct size,
edema formation, and neurological deficits at 48h after
ischemia.
NAD(+) administration also significantly decreased
brain ischemia-induced autophagy in the cortex and hippocampus. We further found that prevention of autophagy by
3-methyladenine (3-MA), a selective autophagy inhibitor, significantly reduced ischemic brain damage, suggesting an important role of autophagy in the ischemic
brain injury in our animal model. Collectively, our findings have suggested that
NAD(+) administration decreases ischemic brain damage at least partially by blocking autophagy. This is the first suggested mechanism regarding the protective effects of
NAD(+) in
cerebral ischemia, which further highlights the promise of
NAD(+) for treating
brain ischemia.